Retatrutide (Reta) is a next-generation triple agonist targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This unique triple-action mechanism has shown strong potential in preclinical studies for significant body weight reduction, enhanced metabolic control, and improved lipid profiles.

Research Applications & Potential Effects:

• Studies on body weight reduction and appetite suppression

• Research into triple incretin pathway synergy

• Investigations into glucose regulation and insulin sensitivity

• Preclinical evaluation of cardiovascular, metabolic, and lipid profile improvements

Supplied as a sterile, lyophilised powder to ensure maximum stability and purity for precise research applications.

Molecular Formula: C196H299N53O60
Molar Mass: 4340.85 g/mol
Form: Lyophilised powder
Purity: ≥ 99% (HPLC)
Storage: Store at −20 °C, protect from light
Intended Use: Strictly for research purposes only. Not for human consumption, medical, or veterinary use.
CAS Number: 3044674-34-8